| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
|
André, F.
|
|
|
35 |
12 |
p. 1169-1180
|
article
|
| 2 |
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
|
Blay, J.-Y.
|
|
|
35 |
12 |
p. 1157-1168
|
article
|
| 3 |
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
|
Blay, J.-Y.
|
|
|
35 |
12 |
p. 1207-1208
|
article
|
| 4 |
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF V600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
|
Ciardiello, D.
|
|
|
35 |
12 |
p. 1105-1115
|
article
|
| 5 |
Corrigendum to “60P Hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: A phase II trial” [Annals of Oncology 33 (2023) S568]
|
Wang, X.
|
|
|
35 |
12 |
p. 1209
|
article
|
| 6 |
Does total neoadjuvant therapy improve overall survival in rectal cancer? Interpretation of the PRODIGE-23 and other studies
|
Socha, J.
|
|
|
35 |
12 |
p. 1204-1205
|
article
|
| 7 |
Duration of adjuvant imatinib treatment in GIST at high risk of relapse
|
Akkus, E.
|
|
|
35 |
12 |
p. 1205-1206
|
article
|
| 8 |
Editorial Board
|
|
|
|
35 |
12 |
p. iii
|
article
|
| 9 |
Elusive biomarkers of sensitivity to combined PD1/CTLA4 blockade in metastatic castration-resistant prostate cancer
|
Antonarakis, E.S.
|
|
|
35 |
12 |
p. 1077-1079
|
article
|
| 10 |
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration ☆
|
Rodon, J.
|
|
|
35 |
12 |
p. 1138-1147
|
article
|
| 11 |
Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial
|
Toh, H.C.
|
|
|
35 |
12 |
p. 1181-1190
|
article
|
| 12 |
How AI will transform cancer care ☆
|
Kather, J.N.
|
|
|
35 |
12 |
p. 1085-1087
|
article
|
| 13 |
Inoperable stage III EGFR mutant non-small-cell lung cancer: time for drug first, local later?
|
John, A.
|
|
|
35 |
12 |
p. 1074-1076
|
article
|
| 14 |
Investigating the ‘liquid–solid interface’ in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatment—where do we draw the line?
|
Beehuat Tan, I.
|
|
|
35 |
12 |
p. 1067-1070
|
article
|
| 15 |
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial ☆
|
van Wilpe, S.
|
|
|
35 |
12 |
p. 1126-1137
|
article
|
| 16 |
Is adjuvant ribociclib ready for prime time?
|
Natarajan, A.
|
|
|
35 |
12 |
p. 1200-1201
|
article
|
| 17 |
Long-term adjuvant therapy for high-risk GIST: towards tailored imatinib duration?
|
Nishida, T.
|
|
|
35 |
12 |
p. 1083-1084
|
article
|
| 18 |
Lung cancer research and treatment: global perspectives and strategic calls to action
|
Meyer, M.-L.
|
|
|
35 |
12 |
p. 1088-1104
|
article
|
| 19 |
Odronextamab against relapsed or refractory follicular lymphoma
|
Shimazu, Y.
|
|
|
35 |
12 |
p. 1208
|
article
|
| 20 |
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study ☆
|
Lu, S.
|
|
|
35 |
12 |
p. 1116-1125
|
article
|
| 21 |
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
|
Long, G.V.
|
|
|
35 |
12 |
p. 1191-1199
|
article
|
| 22 |
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma ☆
|
Agarwal, N.
|
|
|
35 |
12 |
p. 1148-1156
|
article
|
| 23 |
Reply to the manuscript ‘A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse’ by J.-Y. Blay et al.
|
Petrelli, F.
|
|
|
35 |
12 |
p. 1206-1207
|
article
|
| 24 |
Response to letters to the Editor on ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’
|
Goetz, M.P.
|
|
|
35 |
12 |
p. 1202-1204
|
article
|
| 25 |
Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway
|
Boscolo Bielo, L.
|
|
|
35 |
12 |
p. 1080-1082
|
article
|
| 26 |
Table of Contents
|
|
|
|
35 |
12 |
p. i-ii
|
article
|
| 27 |
The global epidemic of early-onset cancer: nature, nurture, or both? ☆
|
Ogino, S.
|
|
|
35 |
12 |
p. 1071-1073
|
article
|
| 28 |
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al
|
De Sanctis, R.
|
|
|
35 |
12 |
p. 1201-1202
|
article
|
Journal description